Skip to main content

Drawing all the Benefits from Pharmaceutical Spending

Buy Article:

$24.00 plus tax (Refund Policy)

OECD countries' pharmaceutical policies generally focus on three main objectives: making medicines accessible and affordable to patients; containing public spending growth, and providing incentives for future innovation. This chapter provides a brief review of current pharmaceutical reimbursement and pricing policies in OECD countries, as well as short‐term measures adopted in response to the economic crisis. It then focuses in particular on two important issues: decisions pertaining to the coverage of new products with high costs and/or uncertain benefits, and the development of generic markets.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Review Article

Publication date: 2010-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more